Every year, about one million new cases of colon cancer are diagnosed worldwide. About 150,000 new cases are detected each year in the United States. Over a lifetime, about 1 in 19 people develop colon cancer and nearly 50,000 people are expected to die from it in the U.S. this year. According to the American Cancer Society, colon cancer is the third leading cause of cancer-related death in the U.S., accounting for about 10 percent of all cancer deaths.
What makes cancer cells different from ordinary cells in our bodies? Can these differences be used to strike at them and paralyze their activity?
A microbe found in the colon and commonly associated with the development of colitis and colon cancer also may play a role in the development of some breast cancers, according to new research from investigators with the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.
Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that a triple drug combination - of irinotecan, cetuximab, and vemurafenib - is a more powerful tumor fighter and keeps people with metastatic colon cancer disease free for a significantly longer period of time compared with patients treated with irinotecan and cetuximab.
With the evolution of cancer, the quest for identifying efficient treatment techniques for cancer patients has remained challenging.
Scientists have long known that therapies that target the cancer-driving MAPK pathway are only effective in a handful of cancers with specific mutations in a cancer gene called BRAF, and these cancers that initially respond to the therapy often end up developing resistance to the treatment, resulting in relapse for many patients.
In breakthrough colon cancer research, scientists at ChristianaCare's Helen F. Graham Cancer Center & Research Institute have discovered a link between two key signaling pathways crucial to the development and growth of colon cancer. The study is published today in the journal PLOS ONE.
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published today in Nature Communications.
Dr. O'Keefe speaks to AZoLifeSciences about his latest research that investigated how the pesco-mediterranean diet may lower the risk for heart disease.
When cancer metastasizes and spreads throughout the body, it can severely change the prognosis of the disease. It is estimated that metastasis is responsible for 90 percent of cancer deaths.
The 1970s revealed the initial data indicating mutations in the genetic material of tumors, much before the first oncogene alterations were identified.
It is a fact that has long baffled doctors: Cancer in the small intestine is quite rare, whereas colorectal cancer, a neighboring though much smaller organ, is one of the leading causes of cancer death for men and women. What is it about the colon that seems to "attract" cancer?
Biomedical engineers at Duke University have engineered a method for simultaneously detecting the presence of multiple specific microRNAs in RNA extracted from tissue samples without the need for labeling or target amplification.
MicroRNAs, are attracting interest relating to human diseases because variations in the expression of miRNAs are often associated with abnormal functions.
Tumors are not a consistent cluster of cells. In fact, colon cancers carry differentiated-like cells, just like the functional cells of the intestinal wall and pluripotent cells—the supposed tumor stem cells.
Having abnormally small red blood cells, a condition known as microcytosis could indicate cancer, according to new research led by a University of Exeter.
A study has discovered a novel means by which bacterial colonies in the small intestine support the generation of regulatory T cells.